Results 101 to 110 of about 2,140,151 (276)
Molecular Oncology, EarlyView.The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg +43 more
wiley +1 more source
BMC Cancer, 2018 Background Quizartinib, an inhibitor of class III receptor tyrosine kinases (RTKs), is currently in phase 3 development for the treatment of acute myeloid leukemia (AML) bearing internal tandem duplications in the FLT3 gene.
Kyriakos P. Papadopoulos +5 more
doaj +1 more source
An Added Dimension to the Faculty Role: The Accelerated Student [PDF]
, 2006 Nursing faculty work hard at helping students achieve academic success by utilizing a variety of support services. The question guiding this study is: Do accelerated and traditional BSN students have different characteristics or different valued support ...
Nelson, Deborah, Rauch, Lisa
core +1 more source
Molecular Oncology, EarlyView.Nanosecond infrared laser (NIRL) low‐volume sampling combined with shotgun lipidomics uncovers distinct lipidome alterations in oropharyngeal squamous cell carcinoma (OPSCC) of the palatine tonsil. Several lipid species consistently differentiate tumor from healthy tissue, highlighting their potential as diagnostic markers.
Leonard Kerkhoff +11 more
wiley +1 more source
, 2013 35 pages, contribution to the CAS - CERN Accelerator School: Advanced Accelerator Physics Course, Trondheim, Norway, 18-29 Aug 2013.
openaire +3 more sources
Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity
Molecular Oncology, EarlyView.Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung +17 more
wiley +1 more source
Probing the last scattering surface through the recent and future CMB observations
, 2008 We have constrained the extended (delayed and accelerated) models of hydrogen recombination, by investigating associated changes of the position and the width of the last scattering surface.
Ade P +32 more
core +1 more source
Molecular Oncology, EarlyView.Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat +8 more
wiley +1 more source
Journal of Current OphthalmologyPurpose: To evaluate the safety and efficacy of increased environmental oxygen using a novel oxygen chamber during corneal cross-linking (CXL) in patients with keratoconus (KCN).
Fateme Alipour +7 more
doaj +1 more source
Correlation of the differential expression of PIK3R1 and its spliced variant, p55α, in pan‐cancer
Molecular Oncology, EarlyView.PIK3R1 undergoes alternative splicing to generate the isoforms, p85α and p55α. By combining large patient datasets with laboratory experiments, we show that PIK3R1 spliced variants shape cancer behavior. While tumors lose the protective p85α isoform, p55α is overexpressed, changes linked to poorer survival and more pronounced in African American ...
Ishita Gupta +10 more
wiley +1 more source